INVESTORS & MEDIA
News Release
Regeneron Converts Interleukin-1 Antibody Opt-In Rights to Royalty Agreement
Under the first royalty agreement, Regeneron is entitled to receive royalties on worldwide sales of Novartis’ canakinumab (ACZ885), a fully human anti-interleukin-IL1β antibody currently under regulatory review to treat cryopyrin-associated periodic syndrome (CAPS) and in development for a number of other inflammatory diseases. On the basis of the same agreement Regeneron waives its rights to opt-in to the development and commercialization of canakinumab.
Under the second royalty agreement,
The financial terms of both agreements are identical in relation to stepped royalties to be paid on the basis of future sales. They do not include any upfront or milestone payments or any sharing of development expenses.
The royalty agreements replace a 2003 collaboration and license
agreement under which Regeneron had the right to opt in to the
development and commercialization of Novartis’ interleukin-1 antibody
and
About
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders. Additional information about Regeneron and recent news releases are available on Regeneron’s web site at www.regeneron.com
Forward Looking Statement
This news release discusses historical information and includes
forward-looking statements about Regeneron and its products, development
programs, finances, and business, all of which involve a number of risks
and uncertainties, such as risks associated with preclinical and
clinical development of Regeneron’s drug candidates, determinations by
regulatory and administrative governmental authorities which may delay
or restrict Regeneron’s ability to continue to develop or commercialize
its product and drug candidates, competing drugs that are superior to
Regeneron’s product and drug candidates, uncertainty of market
acceptance of Regeneron’s product and drug candidates, unanticipated
expenses, the availability and cost of capital, the costs of developing,
producing, and selling products, the potential for any collaboration
agreement, including Regeneron’s agreements with the sanofi-aventis
Group and
Source:
Regeneron Pharmaceuticals, Inc.
Investor Relations
Peter
Dworkin
914.345.7640
peter.dworkin@regeneron.com
or
Media
Relations
Laura Lindsay
914.345.7800
laura.lindsay@regeneron.com